Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.08Last Year’s EPS
0.81Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -19.20%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with significant growth in revenue and profits driven by key blockbuster products. The company announced new growth catalysts and an increased guidance for 2025. However, ongoing litigation with Merck poses a potential risk, though it is not expected to impact the core business. Overall, the highlights significantly outweigh the lowlights.Company Guidance
During Halozyme's first quarter 2025 earnings call, guidance was provided highlighting significant financial growth and future expectations. Total revenue increased by 35% year-over-year to $265 million, driven primarily by a 39% increase in royalty revenue to $168 million from blockbusters like DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. Adjusted EBITDA grew to $162 million, representing a 40% increase, while non-GAAP EPS rose to $1.11, marking similar growth. Net income surged by 54% to $118 million. The company announced a $250 million share repurchase plan for 2025, reflecting strong investor returns, and raised its full-year 2025 guidance, projecting total revenues between $1.2 billion and $1.28 billion, with royalty revenues expected to grow by 31% to 37%.Strong Revenue Growth
Total revenue increased 35% year-over-year to $265 million, with royalty revenue increasing by 39% to $168 million. Adjusted EBITDA increased to $162 million and non-GAAP EPS increased to $1.11, both representing approximately 40% year-over-year growth. Net income grew 54% to $118 million.
Successful Blockbuster Products
DARZALEX subcutaneous sales increased 22% year-over-year to $3.2 billion, Phesgo sales increased 52% to approximately $675 million, and VYVGART Hytrulo contributed significantly to revenue growth. These blockbusters are expected to sustain growth for years.
New Growth Catalysts
11 new growth catalysts were identified, including approvals and market expansions for DARZALEX, Phesgo, and VYVGART Hytrulo, expected to drive growth for multiple years.
Share Repurchase Program
The company announced a $250 million share repurchase plan for 2025, continuing a trend of delivering high IRR through buybacks.
Increased 2025 Guidance
Full-year revenue guidance was raised to $1.2 billion to $1.28 billion, representing year-over-year growth of 18% to 26%.
---
DE:RV7 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:RV7 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | €53.22 | €55.54 | +4.36% |
Feb 18, 2025 | €55.18 | €55.68 | +0.91% |
Oct 31, 2024 | €46.51 | €52.10 | +12.02% |
Aug 06, 2024 | €48.08 | €49.76 | +3.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Halozyme Therapeutics (DE:RV7) report earnings?
Halozyme Therapeutics (DE:RV7) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Halozyme Therapeutics (DE:RV7) earnings time?
Halozyme Therapeutics (DE:RV7) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Halozyme Therapeutics stock?
The P/E ratio of Halozyme is N/A.
What is DE:RV7 EPS forecast?
DE:RV7 EPS forecast for the fiscal quarter 2025 (Q2) is 1.08.
---